Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Reuters

Oct 27

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Oct 27 (Reuters) - Medical equipment maker Revvity RVTY.N on Monday raised its annual profit forecast and beat third-quarter estimates on improving demand for its testing kits in the diagnostics unit.

However, shares of the company fell 2.7% in volatile premarket trading after third-quarter revenue missed estimates.

Quarterly revenue in its diagnostic unit, which provides testing tools, rose 3% to $356.1 million, compared with analysts' estimates of $350.6 million, according to data compiled by LSEG.

Revvity joined peers such as Thermo Fisher TMO.N in reporting renewed demand for contract research and diagnostics services, as pharmaceutical companies ramp up drug development in the U.S. amid evolving trade policies under President Donald Trump.

Earlier this year, Revvity warned of a $135 million hit from Trump's tariffs on China and announced plans to adjust its manufacturing footprint.

The company expects 2025 adjusted profit in the range of $4.90 to $5 per share, compared with its previous forecast of $4.85 to $4.95.

Its third-quarter revenue of $699 million missed estimates of $700.5 million, while adjusted profit of $1.18 per share beat expectations of $1.14.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath)

((siddhi.mahatole@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578610687"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578610687\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578610687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578610687","market":"us","top_or_hot":-1,"title":"Revvity lifts annual profit forecast on renewed demand in diagnostics unit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Revvity lifts annual profit forecast on renewed demand in diagnostics unit</title></head><body><p>\n<span>Oct 27 (Reuters)</span><span> - </span>Medical equipment maker Revvity <span>RVTY.N</span> on Monday raised its annual profit forecast <span>and beat third-quarter estimates </span>on improving demand for its testing kits in the diagnostics unit.</p><p>\n<span>However, shares of the company fell 2.7% in volatile premarket trading after third-quarter revenue missed estimates.</span>\n</p><p><span>Quarterly revenue in its diagnostic unit, which provides testing tools, rose 3% to $356.1 million, compared with analysts' estimates of $350.6 million, according to data compiled by LSEG.</span></p><p>Revvity joined peers <span>such as </span><span>Thermo Fisher</span> <span>TMO.N</span> in reporting renewed demand for contract research and diagnostics services, as pharmaceutical companies ramp up drug development in the U.S. amid evolving trade policies under President Donald Trump.     </p><p>\n<span>Earlier this year, </span>Revvity warned of a $135 million hit from Trump's tariffs on China and <span>announced plans </span>to adjust its manufacturing footprint.    </p><p>\n         The company expects 2025 adjusted profit in the range of $4.90 to $5 per share, compared with its previous forecast of  $4.85 to $4.95. </p><p><span>Its third-quarter revenue of $699 million missed estimates of $700.5 million, while adjusted profit of $1.18 per share beat expectations of $1.14.</span></p><p> (Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath)</p><p> ((siddhi.mahatole@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revvity lifts annual profit forecast on renewed demand in diagnostics unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevvity lifts annual profit forecast on renewed demand in diagnostics unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-27 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Revvity lifts annual profit forecast on renewed demand in diagnostics unit</title></head><body><p>\n<span>Oct 27 (Reuters)</span><span> - </span>Medical equipment maker Revvity <span>RVTY.N</span> on Monday raised its annual profit forecast <span>and beat third-quarter estimates </span>on improving demand for its testing kits in the diagnostics unit.</p><p>\n<span>However, shares of the company fell 2.7% in volatile premarket trading after third-quarter revenue missed estimates.</span>\n</p><p><span>Quarterly revenue in its diagnostic unit, which provides testing tools, rose 3% to $356.1 million, compared with analysts' estimates of $350.6 million, according to data compiled by LSEG.</span></p><p>Revvity joined peers <span>such as </span><span>Thermo Fisher</span> <span>TMO.N</span> in reporting renewed demand for contract research and diagnostics services, as pharmaceutical companies ramp up drug development in the U.S. amid evolving trade policies under President Donald Trump.     </p><p>\n<span>Earlier this year, </span>Revvity warned of a $135 million hit from Trump's tariffs on China and <span>announced plans </span>to adjust its manufacturing footprint.    </p><p>\n         The company expects 2025 adjusted profit in the range of $4.90 to $5 per share, compared with its previous forecast of  $4.85 to $4.95. </p><p><span>Its third-quarter revenue of $699 million missed estimates of $700.5 million, while adjusted profit of $1.18 per share beat expectations of $1.14.</span></p><p> (Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath)</p><p> ((siddhi.mahatole@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DHR","symbol_name":"丹纳赫","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nL4N3W80OX:1","article_id":"2578610687","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578610687","pubTimestamp":1761563069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oct 27  - Medical equipment maker Revvity RVTY.N on Monday raised its annual profit forecast and beat third-quarter estimates on improving demand for its testing kits in the diagnostics unit.However, shares of the company fell 2.7% in volatile premarket trading after third-quarter revenue missed estimates.Quarterly revenue in its diagnostic unit, which provides testing tools, rose 3% to $356.1 million, compared with analysts' estimates of $350.6 million, according to data compiled by LSEG.Revvity joined peers such as Thermo Fisher TMO.N in reporting renewed demand for contract research and diagnostics services, as pharmaceutical companies ramp up drug development in the U.S. amid evolving trade policies under President Donald Trump.Earlier this year, Revvity warned of a $135 million hit from Trump's tariffs on China and announced plans to adjust its manufacturing footprint.The company expects 2025 adjusted profit in the range of $4.90 to $5 per share, compared with its previous forecas","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DHR":"丹纳赫","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1923621640.USD":"Natixis Thematics Water R/A USD","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU2360108059.USD":"BGF CIRCULAR ECONOMY \"A4\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4504":"桥水持仓","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","RVTY":"REVVITY INC","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4121":"生命科学工具和服务","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","TMO":"赛默飞世尔"},"translate_title":"由于诊断部门的新需求，Revvity上调年度利润预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":0.9,"RVTY":0.9,"TMO":0.9},"content_text":"Revvity lifts annual profit forecast on renewed demand in diagnostics unit\nOct 27 (Reuters) - Medical equipment maker Revvity RVTY.N on Monday raised its annual profit forecast and beat third-quarter estimates on improving demand for its testing kits in the diagnostics unit.\nHowever, shares of the company fell 2.7% in volatile premarket trading after third-quarter revenue missed estimates.\nQuarterly revenue in its diagnostic unit, which provides testing tools, rose 3% to $356.1 million, compared with analysts' estimates of $350.6 million, according to data compiled by LSEG.Revvity joined peers such as Thermo Fisher TMO.N in reporting renewed demand for contract research and diagnostics services, as pharmaceutical companies ramp up drug development in the U.S. amid evolving trade policies under President Donald Trump.     \nEarlier this year, Revvity warned of a $135 million hit from Trump's tariffs on China and announced plans to adjust its manufacturing footprint.    \n         The company expects 2025 adjusted profit in the range of $4.90 to $5 per share, compared with its previous forecast of  $4.85 to $4.95. Its third-quarter revenue of $699 million missed estimates of $700.5 million, while adjusted profit of $1.18 per share beat expectations of $1.14. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath) ((siddhi.mahatole@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}